[{"id":"ca5731f4-d6d7-4d7f-a3e2-390ca029a12d","acronym":"CRUKD/22/002","url":"https://clinicaltrials.gov/study/NCT05057013","created_at":"2021-09-27T12:52:51.886Z","updated_at":"2024-07-02T16:35:52.785Z","phase":"Phase 1/2","brief_title":"HMBD-001 in Advanced HER3 Positive Solid Tumours","source_id_and_acronym":"NCT05057013 - CRUKD/22/002","lead_sponsor":"Cancer Research UK","biomarkers":" ERBB3 • NRG1","pipe":" | ","alterations":" ERBB3 expression • RAS wild-type • NRG1 fusion • ERBB3 overexpression","tags":["ERBB3 • NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression • RAS wild-type • NRG1 fusion • ERBB3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 11/10/2021","start_date":" 11/10/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-03-21"}]